Equities Analysts Set Expectations for TCRX FY2024 Earnings

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Equities research analysts at Lifesci Capital reduced their FY2024 earnings per share (EPS) estimates for shares of TScan Therapeutics in a report issued on Tuesday, November 12th. Lifesci Capital analyst S. Slutsky now forecasts that the company will post earnings per share of ($1.08) for the year, down from their prior forecast of ($1.07). The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.17) per share. Lifesci Capital also issued estimates for TScan Therapeutics’ FY2025 earnings at ($1.08) EPS.

TScan Therapeutics (NASDAQ:TCRX) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.02. The company had revenue of $0.54 million during the quarter, compared to analyst estimates of $1.55 million. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%.

A number of other research firms have also commented on TCRX. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of TScan Therapeutics in a report on Tuesday, August 13th. Wedbush reissued an “outperform” rating and issued a $10.00 target price on shares of TScan Therapeutics in a report on Tuesday, November 5th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $11.00 target price on shares of TScan Therapeutics in a report on Tuesday. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $12.00.

TScan Therapeutics Stock Down 8.2 %

TScan Therapeutics stock opened at $4.82 on Friday. The firm has a market cap of $255.32 million, a price-to-earnings ratio of -4.55 and a beta of 0.79. The stock has a fifty day simple moving average of $5.33 and a two-hundred day simple moving average of $6.51. TScan Therapeutics has a 12 month low of $3.73 and a 12 month high of $9.69. The company has a current ratio of 9.56, a quick ratio of 7.77 and a debt-to-equity ratio of 0.13.

Institutional Investors Weigh In On TScan Therapeutics

Several large investors have recently made changes to their positions in the company. Tocqueville Asset Management L.P. bought a new stake in TScan Therapeutics during the first quarter worth approximately $1,685,000. Vanguard Group Inc. increased its stake in TScan Therapeutics by 1.1% during the first quarter. Vanguard Group Inc. now owns 1,808,152 shares of the company’s stock worth $14,357,000 after acquiring an additional 20,000 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in TScan Therapeutics during the second quarter worth approximately $682,000. Rhumbline Advisers bought a new stake in TScan Therapeutics during the second quarter worth approximately $274,000. Finally, American Century Companies Inc. increased its stake in TScan Therapeutics by 48.9% during the second quarter. American Century Companies Inc. now owns 47,481 shares of the company’s stock worth $278,000 after acquiring an additional 15,596 shares during the last quarter. 82.83% of the stock is owned by institutional investors.

Insider Activity at TScan Therapeutics

In other news, Director Barbara Klencke bought 5,000 shares of TScan Therapeutics stock in a transaction dated Monday, August 26th. The shares were purchased at an average cost of $5.53 per share, with a total value of $27,650.00. Following the completion of the acquisition, the director now owns 40,000 shares of the company’s stock, valued at $221,200. This trade represents a 14.29 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Zoran Zdraveski sold 164,686 shares of TScan Therapeutics stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $5.78, for a total value of $951,885.08. Following the completion of the sale, the insider now directly owns 4,716 shares in the company, valued at $27,258.48. This trade represents a 97.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have purchased 15,000 shares of company stock worth $82,550. Corporate insiders own 2.76% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.